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Abstract

Author Manuscript

Pseudoxanthoma elasticum (PXE), an autosomal recessive disorder characterized by ectopic
mineralization, is caused by mutations in the ABCC6 gene. We examined clinically 29 Chinese
PXE patients from unrelated families, so far the largest cohort of Asian PXE patients. In a subset
of 22 patients, we sequenced ABCC6 and another candidate gene, ENPP1, followed by
pathogenicity analyses for each variant. We identified a total of 17 distinct mutations in ABCC6,
15 of them being previously unreported, including 5 frame-shift and 10 missense variants. In
addition, a missense mutation in combination with a recurrent nonsense mutation in ENPP1 was
discovered in a pediatric PXE case. No cases with p.R1141X or del23-29 mutations, common in
Caucasian patient populations, were identified. The 10 missense mutations in ABCC6 were
expressed in mouse liver via hydrodynamic tail-vein injections. One mutant protein showed
cytoplasmic accumulation indicating abnormal subcellular trafficking, while the other nine
mutants showed correct plasma membrane location. These nine mutations were further
investigated for their pathogenicity using a recently developed zebrafish mRNA rescue assay.
Minimal rescue of the morpholino-induced phenotype was achieved with 8 of the 9 mutant human
ABCC6 mRNAs tested, implying pathogenicity. This study demonstrates that the Chinese PXE
population harbors unique ABCC6 mutations. These genetic data have implications for allelespecific therapy currently being developed for PXE.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE), the prototype of heritable ectopic mineralization
disorders, is characterized by late-onset, yet progressive, calcium hydroxyapatite deposition
on elastic structures in peripheral connective tissues (Neldner, 1988; Uitto et al., 2010).
Clinically, PXE manifests with characteristic cutaneous, ocular and cardiovascular findings.
The disease is inherited in an autosomal recessive manner with apparently complete
penetrance, and ABCC6 has been identified as the gene harboring mutations in most patients
with PXE (Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil et al., 2000; Struk et al.,
2000). This gene encodes ABCC6, a putative transmembrane efflux transporter protein
primarily expressed in the baso-lateral plasma membranes of hepatocytes and to a lesser
extent in the proximal tubules of the kidneys.

Author Manuscript

In addition to ABCC6, recent studies have disclosed mutations in the ENPP1 gene in some
patients with PXE-like cutaneous findings, often associated with extensive vascular
mineralization (Kalah et al., 2012; Li et al., 2012). ENPP1 mutations also underlie a severe
ectopic mineralization disorder, generalized arterial calcification of infancy (GACI), an
autosomal recessive disease, which affects primarily the arterial blood vessels (Ruf et al.,
2005; Rutsch et al., 2003). This disease is commonly diagnosed by pre- or perinatal
ultrasound, and the affected individuals in most cases die within the first year of life from
cardiovascular complications. While most cases of GACI are caused by mutations in the
ENPP1, ABCC6 mutations have also been demonstrated in some patients (Li et al., 2014;
Nitschke et al., 2012). Thus, there is considerable phenotypic and genotypic overlap
between PXE and GACI (Li and Uitto, 2013; Nitschke and Rutsch, 2012).

Author Manuscript

Over 300 distinct mutations in the ABCC6 gene have been identified in patients with PXE,
two common recurrent mutations, p.R1141X and genomic deletion of exons 23 through 29
(c.2996-1724_4209-478del; referred to as del23-29), representing 18.5 and 9.9% of all
reported mutant alleles, respectively (Pfendner et al., 2007; Terry and Hefferson, 2013;
Uitto et al., 2013). However, essentially all published studies have focused on PXE in
Caucasian patient populations, and very few mutations have been reported in patients of
Asian ancestry. In this study, we have investigated a cohort of 29 Chinese PXE patients
from unrelated families, so far the largest cohort of Asian PXE patients. Genetic analysis of
22 patients revealed a mutation profile clearly distinct from that found in Caucasian patients,
and the Chinese PXE patients harbor unique mutations.

RESULTS
Author Manuscript

Identification of ABCC6 Mutations
A cohort of 29 Chinese patients with PXE was examined, and the diagnosis was initially
suggested by characteristic cutaneous lesions and histopathology using routine
Hematoxylin-Eosin as well as Verhoeff van Gieson and von Kossa stains for elastic
structures and mineralization, respectively (Uitto et al., 2014) (Fig. S1). The majority of
patients were females (26/29), most of them had the onset at less than 30 years of age, and
the majority of patients (~90%) had the disease for over 6 years since diagnosis at the time
of the study (Table S1).
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In a subset of 22 patients, DNA, isolated from either peripheral blood leukocytes or paraffinembedded skin biopsies, was available and subjected to mutation analysis first using a
strategy and primers that we have previously developed for streamlined mutation detection
in the ABCC6 gene (LaRusso et al., 2010; Pfendner et al., 2007). A total of 36 sequence
variants in ABCC6 were discovered. These variants included 6 small insertion or deletion
mutations resulting in premature termination codon (PTC), and these variants were
considered pathogenic (Fig. 1A). Among the 30 single nucleotide substitutions, we
identified 7 synonymous mutations while 23 were missense mutations. Among the
nonsynonymous substitutions, 9 were present in the single nucleotide polymorphism (SNP)
database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
geneId=368&ctg=NT_010393.16&mrna=NM_001171.5&prot=NP_001162.4&orien=forwa
rd) in frequency >1% and were therefore considered to be nonpathogenic polymorphisms.
Among the 14 amino acid substitutions not present in the SNP database, one of them, c.
3341G>A, has been previously reported as a pathogenic mutation. The remaining 13 amino
acid substitutions were examined for potential pathogenicity by PolyPhen-2 and SIFT
prediction programs (Table 1), and 10 putative missense variants were examined for
subcellular localization in mouse hepatocyte plasma membrane targeting assay and for
functional pathogenicity in zebrafish mRNA rescue assay in vivo (see below). Among the
putative pathogenic mutations, only two of them, one missense and one single-nucleotide
deletion mutation, have been published previously. Most notably, none of the Chinese PXE
patients had the recurrent p.R1141X or del23-29 mutation. When examined individually, 13
patients were homozygous or compound heterozygous with mutations in both alleles of
ABCC6, while in 7 patients only one mutation was found. In the latter cases, search for
ENPP1 mutations was unyielding.
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Assay of membrane targeting of the mutant protein
Among the discovered sequence variants, 13 of them resulted in amino acid substitution
(Table 1 and Fig. 1B), and they all were initially considered pathogenic because searches of
the SNP database did not report the presence of these variants or they were present in
frequency of less than 1%. Analysis of the potential functional consequences of these
mutations at the protein level by SIFT and PolyPhen-2 bioinformatics programs predicted
that 6 of them were definitely damaging/probably disruptive while the remaining 7 were
tolerated or benign (Table 1). In the latter group, three variants, even though not present in
the SNP database, were recurrent in the Chinese families with PXE in high frequency, and
they were considered nonpathogenic and not studied further.

Author Manuscript

Theoretically, missense mutations could inactivate the ABCC6 activity by a number of
mechanisms. First, it is possible that the mutant protein is mis-localized within the
hepatocytes and does not migrate into the appropriate plasma membrane location on the
baso-lateral surface of hepatocytes (Aranyi et al., 2013). Alternatively, the protein is
appropriately targeted to the correct membrane location but the transporter activity is
compromised by inability of the protein to perform its transport function, for example due to
deficient binding and hydrolysis of ATP (Ilias et al., 2002). We first determined the
subcellular localization of the human mutant protein expressed from an expression vector
under the control of a liver-specific mouse albumin promoter delivered to the mouse liver by
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hydrodynamic injection through the tail vein (Jiang et al., 2010). After 3 days of delivery,
the livers were harvested, and the subcellular localization of the human as well as
endogenous mouse ABCC6 protein was determined by immuno staining with antibodies that
differentially recognize human and mouse protein epitopes (Fig. 2). As demonstrated
previously, the endogenous mouse ABCC6 protein resides at the baso-lateral surface of the
hepatocyte plasma membrane (Pomozi et al., 2013). Similarly, 9 out of the 10 human mutant
proteins tested in this study were co-localized with the mouse protein at the proper
membrane location (Fig. 2A). However, one mutation, p.L605P, did not allow the protein to
migrate to the plasma membrane, and the mutant protein was localized exclusively in the
cytoplasm (Fig. 2A and B). Similarly, another, previously identified mutation, p.R1114P,
resulted in partial retention of the protein in the cytoplasm while some cells demonstrated
plasma membrane staining (Aranyi et al., 2013) (Fig. 2B).
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A chaperone compound, 4-phenylbutyrate (4-PBA), has previously been shown to facilitate
transfer of some mutant mis-targeted ABCC6 molecules from the cytoplasm to the plasma
membrane (Aranyi et al., 2013). Consequently, we tested the effect of 4-PBA on the
subcellular localization of the p.L605P and p.R1114P mutants by treating mice with this
compound two days prior and four days following the injection of the expression construct
for a total of 6 days. 4-PBA clearly facilitated the transfer of the cytoplasmic mutant
p.R1114P protein to the plasma membrane, as shown previously (Pomozi et al., 2014) (Fig.
2B). However, this compound had no effect on the subcellular localization of the protein
harboring the mutation p.L605P. Thus, 4-PBA may be of help in facilitating the proper
targeting of some, but not all, mutant ABCC6 proteins to the plasma membrane.
Demonstration of pathogenicity in zebrafish mRNA rescue assay
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The pathogenicity of the missense mutations identified in ABCC6 was further investigated in
a zebrafish mRNA rescue assay that we have recently developed (Li et al., 2010a; Zhou et
al., 2013). In this assay, zebrafish embryos are injected with an abcc6a morpholino which
causes knock-down of the corresponding gene expression. As a consequence, the zebrafish
embryos develop a profound phenotype consisting of pericardiac edema, stunted growth and
curled tail, and the developing embryos die before the age of 7 days post fertilization (dpf)
(Fig. 3). This phenotype can be fully rescued by injection of wild-type human ABCC6
mRNA together with the morpholino (Fig. 3). We consequently injected zebrafish embryos
with the morpholino together with human ABCC6 mRNA harboring missense mutations
identified in this study. As a negative control, the morpholino was injected with the human
mRNA harboring stop codon mutation p.R1141X. As shown in Fig. 3, this mRNA
containing the nonsense mutation did not rescue the phenotype. Injection of mutant mRNAs
harboring the missense mutations identified in this study together with the morpholino
revealed that 8 out of 9 mutations tested did not provide significant rescue as judged by
either morphology of the zebrafish embryos (Fig. 3) or by the percent of lethality (Table 2)
at 4 dpf, suggesting that they are pathogenic. Only one mutant mRNA, p.R64Q, resulted in
rescue comparable to that of the wild-type mRNA (Fig. 3 and Table 2). However, the
corresponding mutation, c.191G→A, was not present in the SNP database, and it is unclear
whether this is a pathogenic mutation in the 5 patients with PXE.

J Invest Dermatol. Author manuscript; available in PMC 2015 November 01.

Jin et al.

Page 5

Identification of mutations in the ENPP1 gene
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A male patient diagnosed as having PXE by the presence of characteristic cutaneous
findings and histopathology of the skin did not reveal the presence of mutations in ABCC6
(Fig. 4). Careful examination of the patient revealed several unusual features. First, the
patient’s cutaneous findings had been noted definitely to be present as early as at 8 years of
age categorizing him with a diagnosis of pediatric PXE. Furthermore, in addition to
characteristic yellowish papules in the axillary fossa, the patient had large areas of
hyperpigmented lesions on the trunk, a finding not characteristic of PXE (Fig. 4A). With the
notion that mutations have been recently disclosed in the ENPP1 gene in patients with
cutaneous PXE-like lesions (Kalah et al., 2012; Li et al., 2012), we next sequenced ENPP1,
which identified 2 heterozygous mutations, p.Y261X and p.S479F, and the parents were
heterozygous carriers, respectively (Fig. 4B and D). The nonsense mutation, p.Y261X, has
been previously reported (Ruf et al., 2005). Sequence alignments indicated that serine at the
amino acid position 479 is highly conserved during evolution (Fig. 4C). This sequence
variant, p.S479F, was not present in the SNP database, and this mutation was predicted to be
probably damaging (0.99) and damaging (0), when analyzed by PolyPhen-2 and SIFT
programs, respectively. Collectively, the mutation analysis in the Chinese cohort of PXE
demonstrated considerable genetic heterogeneity and identified a number of mutations not
previously reported in the literature.

DISCUSSION
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Understanding of the mechanisms leading to aberrant mineralization of connective tissues
has been advanced by observations on a group of heritable disorders manifesting with
ectopic mineralization. The prototype of such conditions is PXE, an autosomal recessive
disorder which affects a number of organs by ectopic mineralization, with primary clinical
findings in the skin, the eyes, and the cardiovascular system (Neldner, 1988; Uitto et al.,
2010). PXE is a rare disorder, with an estimated prevalence of ~1:50,000 which would
imply that there are ~7,000 to 8,000 affected individuals in the United States, and with the
same prevalence as many as 50,000 patients in China. The diagnosis of PXE is made by a
combination of clinical findings in the skin and the eyes, supported by histopathologic and
molecular diagnostic observations (Uitto et al., 2014). While the manifestations of PXE are
of late onset and the disease progresses slowly, PXE is associated with major clinical
complications, including loss of central vision often leading to blindness, and occurrence of
catastrophic cardiovascular events, including early myocardial infarcts and strokes. There is
a considerable spectrum of phenotypic presentations and severity of the disease: At one end
of the spectrum, young patients in their infancy, with considerable vascular involvement,
have been diagnosed with PXE-like cutaneous findings, often classified as pediatric PXE (Li
et al., 2013; Li et al., 2014). In addition, patients with GACI, typically caused by mutations
in the ENPP1 gene, can demonstrate PXE-like findings, supporting the notion that there is
considerable both clinical and genetic overlap between PXE and GACI (Nitschke and
Rutsch, 2012).
The classic form of PXE is caused by mutations in the ABCC6 gene, and over 300 distinct
mutations have been identified representing well over 1,000 mutant alleles (Terry and
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Hefferson, 2013). Among the published mutations, two common recurrent mutations,
p.R1141X and del23-29, account for up to 30% of all mutant alleles (Pfendner et al., 2007;
Terry and Hefferson, 2013). Examination of the ancestry and geographic distribution of
patients in the ABCC6 mutation databases reveals that most patients tested are apparently
Caucasians from the United States or European countries, and specific reports of mutations
in the Italian, French and German cohorts have been published (Chassaing et al., 2007;
Gheduzzi et al., 2004; Pfendner et al., 2007; Schulz et al., 2006). Examination of the
mutation database indicates that the frequent p.R1141X mutation is distributed widely
across Europe, while deletion of exons 23-29 (del23-29) is encountered in Northern Europe
and in Northern Mediterranean countries (LaRusso et al., 2010). In addition, limited
numbers of patients, with specific mutations, have been reported from Greece, Turkey,
South Africa and Brazil (Akoglu et al., 2014; Faria et al., 2013; LaRusso et al., 2010; Le
Saux et al., 2002; Ramsay et al., 2009). There is a striking paucity of mutation reports on
individuals of Asian ancestry. Specifically, there are only four distinct mutations reported in
Japanese patients with PXE, and in addition, six ABCC6 sequence variants have been
identified as a cause of angioid streaks in Japanese patients, an eye finding often associated
with PXE (Noji et al., 2004; Sato et al., 2009; Tanioka et al., 2014; Yoshida et al., 2005).
There is only one ABCC6 mutation reported in a Chinese patient with PXE (Yang et al.,
2008).
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In the present study, we have clinically examined a cohort of 29 Chinese patients with PXE,
and DNA was available to specifically sequence the exons and flanking intronic sequences
of ABCC6 in a subset of 22 patients. Among the 36 sequence variants identified in ABCC6,
six small insertions or deletions were causing PTCs, five of them being previously
unreported. Among the 23 nonsynonymous missense mutations, ten were initially
considered potentially pathogenic based on their absence or presence in low frequency
(<1%) in SNP database, and as judged by bioinformatics prediction programs PolyPhen-2
and SIFT to be damaging to the protein function. Among the 10 putative pathogenic
missense mutations tested in zebrafish mRNA rescue assay, nine of them did not provide
rescue, confirming the pathogenic nature of the amino acid substitutions. Only one of the
mutant mRNAs, harboring mutation p.R64Q, was able to rescue the zebrafish phenotype,
similar to that of wild-type mRNA. However, this mutation was not present in the SNP
database and three of the five patients with this sequence variant had another allelic ABCC6
mutation. Therefore, it is unclear whether this mutation, p.R64Q, is pathogenic or not. It
should be noted that no ABCC6 or ENPP1 mutations were found in two patients, and the
overall rate of detection of mutations in ABCC6 and ENPP1 was 80 percent (35 mutant
alleles of a total 44). It should be noted that, the mutation detection strategy utilized PCR
amplification of individual exons and flanking intronic sequences. This approach does not
detect mutations in the regulatory upstream sequences or in the 3′-UTR, deeper intronic
sequences, or large insertions or deletions (Pfendner et al., 2007).
The consequences of missense mutations were also tested in vivo in a mouse system which
examines the subcellular targeting of the mutant protein in mouse hepatocytes following
hydrodynamic delivery of an expression vectors through the tail vein. The wild-type ABCC6
protein localizes to the basolateral surface of hepatocytes, and 9 out of 10 tested missense
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mutations allowed the protein to target the physiological plasma membrane location. Only
one mutation, p.L605P, resulted in cytoplasmic localization of the mutant protein.
Previously, the mutant protein harboring p.R1114P mutation has been shown to remain in
cytoplasmic localization which could be corrected by treatment with 4-PBA, a chaperone
molecule. However, treatment of mice expressing miss-targeted protein with p.L605P
mutation did not result from correction of the subcellular localization. Thus, 4-PBA
treatment may be applicable for correction of the subcellular localization only to selected
mutant ABCC6 proteins with missense mutations.
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One of the patients was diagnosed as PXE manifested with somewhat unusual features,
including relatively early age at onset and presence of atypical cutaneous findings, such as
extensive hyperpigmentation on the trunk, not a characteristic feature of PXE. Analysis of
the ABCC6 gene failed to identify mutations, but subsequent sequencing of the ENPP1,
typically associated with GACI, revealed the presence of a nonsense mutation, p.Y261X,
and a heterozygous missense mutation, p.S479F. The latter mutation is pathogenic, based on
its absence from the SNP database, conservation of the serine-479 through evolution from
zebrafish to human, and prediction by PolyPhen-2 and SIFT programs as damaging. This
previously unreported missense mutation contributes to the growing database of ENPP1
mutations, and this case also illustrates the phenotypic overlap between PXE and GACI. It
should be noted that mutations in the ENPP1 gene have been recently identified in Cole
disease, a rare autosomal dominant genodermatosis featuring punctate keratoderma, patchy
hypopigmentation, and uncommonly, cutaneous calcifications (Eytan et al., 2013). These
observations may have relevance to pigmentary changes noted in our patient diagnosed with
pediatric PXE.
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Collectively, this study identified 16 mutations, 15 of them in ABCC6 and 1 in ENPP1, in
the Chinese PXE population, with implications for accurate diagnosis and subclassification.
This information can be used for genetic counseling, and it forms the basis for prenatal
testing and preimplantation genetic diagnosis in future pregnancies in families at risk for
recurrence. Knowledge of the specific mutations can also be used for presymptomatic
testing in families with known history of PXE (Akoglu et al., 2014; Li et al., 2010b).
Important for the patients, identification of the precise nature of the mutations underlying
the PXE phenotype provides a basis for development of treatment modalities tailored to be
allele specific.

MATERIAL AND METHODS
Patient samples

Author Manuscript

A total of 29 unrelated patients with the putative diagnosis of PXE were investigated.
Informed consent was obtained from all subjects, and the present study was approved by the
local Medical Research Ethics Committee at Xijing Hospital, Fourth Military Medical
University, Xi’an, China. The primary diagnosis of PXE was based on dermatological,
ophthalmologic, and/or histopathologic evaluations (Uitto et al., 2014). In each proband, the
skin lesions were histologically confirmed to be consistent with the diagnosis of PXE by the
observation of calcified elastic fibers in biopsy specimens upon hematoxylin and eosin,
Verhoeff van Gieson and/or von Kossa stains with standard protocols.
J Invest Dermatol. Author manuscript; available in PMC 2015 November 01.
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Mutation analysis
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Genomic DNA was isolated from peripheral blood leukocytes or paraffin embedded skin
tissues from 22 patients from whom samples were available, according to standard
procedures. Mutation detection comprised polymerase chain reaction (PCR) amplification of
each of the 31 exons in the ABCC6 gene using primer pairs placed on the flanking intronic
sequences (Pfendner et al., 2007). This protocol excludes amplification of the two ABCC6
pseudogenes with sequences corresponding to the 5′end of ABCC6 (Pulkkinen et al., 2001).
Purified PCR products were sequenced for variants by comparison with the published cDNA
sequence (Gen Bank accession no. NM_001171). The samples in which no mutations were
found in the ABCC6 gene were further analyzed for the ENPP1 gene using the same
strategy. Evolutionary conservation of the amino acid residue serine-479 in ENPP1 was
examined by sequence alignment with Ensemble program.
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Mice
Immunodeficient Rag1−/− mice in C57/BL6 background (strain: 002216F; Jackson Labs,
Bar Harbor, ME), which are wild-type for Abcc6, were used in this study. The mice were
maintained under standard laboratory conditions and were handled in accordance with the
guidelines for animal experiments by the Institutional Animal Care and Use Committee of
Thomas Jefferson University.
Reagents, plasmid and site-directed mutagenesis
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Sodium 4-phenylbutyrate (4-PBA) was purchased from Sigma-Aldrich (Deisenhofen,
Germany) and dissolved in 0.9% NaCl prior to use. A full-length wild-type human ABCC6
cDNA was cloned into pLIVE™ expression vector purchased from Mirus (MIR5420,
Madison, WI). Using this cDNA as a template, ten different ABCC6 missense DNAconstructs were obtained by site-directed mutagenesis following the manufacturer’s
instructions (Agilent, Santa Clara, CA).
Liver-specific expression of ABCC6 variants in mice
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Liver-specific expression of ABCC6 variants was performed in mice as described in our
previous studies (Jiang et al., 2010; Jiang et al., 2006; Pomozi et al., 2014) Briefly, pLIVE
expression vector (Mirus Bio, Madison, WI) containing the wild-type or mutant ABCC6 was
delivered into the mice by hydrodynamic tail-vein injection of 10% body volume of
TransIT-QR hydrodynamic delivery solution (Mirus), as recommended by the
manufacturer’s instructions, using a 26-gauge syringe needle. At least three mice were
injected with each form of the human ABCC6 cDNA. Mice were sacrificed 3–4 days after
hydrodynamic tail vein injections and the livers were harvested for immunofluorescence.
4-PBA treatment of mice
Mice received intraperitoneal injection of 4-PBA (100 mg/kg per day), once a day for 4 days
initiated at the time of hydrodynamic tail-vein injection, and they additionally received an
approximate dosage of 1000 mg/kg per day in the drinking water, two days prior and four
days following the injection, for a total of 6 days.
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Immunofluorescence
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Immunofluorescence was performed on 8-μm thick frozen liver sections. Slices were fixed
in methanol and then washed with PBS. After incubation in blocking buffer for 13hour, the
primary antibody recognizing human ABCC6 protein (M6II-7, 1:100; abcam, Cambridge,
MA) was added first for 1 hour, followed by incubation with the primary antibody specific
for mouse ABCC6 protein (s-20, 1:200; Santa Cruz, Dallas, Texas) for 13hour. After
washing with PBS, the sections were incubated with secondary antibodies for 1 hour and the
nuclei were stained with 4′, 6-diamidino-2-phenylindole for 53minutes. The stained samples
were analyzed using a fluorescent microscope (Zeiss, Göttingen, Germany).
Zebrafish mRNA rescue assay
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To test the potential pathogenicity of ABCC6 missense mutations, a zebrafish mRNA rescue
assay was performed as described previously (Li et al., 2010a; Zhou et al., 2013). Briefly,
human ABCC6 variants were cloned in Bluescript II SK- vector, and mRNA was generated
by in vitro transcription using the mMessage mMachine kit (Ambion, Austin, TX). A
morpholino specific for zebrafish abcc6a sequence was injected into one- to four-cell-stage
embryos either alone or in combination with the human, either mutant or wild-type ABCC6
mRNA (2.4 mmol). The injected zebrafish embryos were followed for their phenotype and
survival rate on daily intervals.
Ethics Statement
Informed written consent was obtained from all subjects, and the present study was
approved by the local Medical Research Ethics Committee at Xijing Hospital, Fourth
Military Medical University, Xi’an, China.
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The mice were maintained under standard laboratory conditions and were handled in
accordance with the guidelines for animal experiments by the Institutional Animal Care and
Use Committee of Thomas Jefferson University.
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Abbreviations
PXE

pseudoxanthoma elasticum

GACI

generalized arterial calcification of infancy

Pi

inorganic phosphate

PPi

inorganic pyrophosphate

PTC

premature termination codon

SNP

single nucleotide polymorphism

4-PBA

4-phenylbutyrate
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Figure 1. The positions of ABCC6 mutations identified in Chinese patients with PXE
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(a) Intron-exon organization of ABCC6 gene. Vertical boxes represent the 31 exons;
Missense mutations are shown above, and insertion or deletion mutations resulting in PTC
below the line; Green exons code for the two nucleotide-binding fold domains of the
protein; Black, previously reported mutations; Red, to our knowledge previously unreported
mutations; *denotes the presence of the mutation in multiple alleles/patients with the
number of affected alleles in parenthesis. (b) Positions of the missense variants in the
membrane topology model of the ABCC6 protein. The various protein domains are
delineated by horizontal arrows above; the positions of amino acid variants investigated in
the study are in red; nucleotide binding fold domains and intracellular loops are colored with
gray and blue, respectively.
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Figure 2. Subcellular localization of human ABCC6 missense variants expressed in mouse liver,
and the effect of 4-phenylbutyrate (4-PBA) on their localization
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(a) The human (red) and mouse (green) ABCC6 proteins were detected on frozen sections of
mouse liver by immunofluorescence with species specific primary antibodies three days
after hydrodynamic tail vein injection of each ABCC6 missense variant in an expression
vector. (b) Mice injected with ABCC6 missense variants were treated with (b, right panels)
or without (b, left panels) 4-PBA. Scale bar = 100 mm.
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Figure 3. Morphology of zebrafish 4 days after co-injection of an ABCC6A knock-down
morpholino together with different human ABCC6 mRNA variants
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The morpholino-induced phenotype consisting of pericardiac edema, stunted growth and
curled tail, similar to zebrafish injected with morpholino (MO) alone, was observed in
zebrafish co-injected with human ABCC6 mRNA carrying p.R1141X, p.P4H, p.A9E,
p.P21S, p.R419Q, p.E125K, p.E709G or p.L948P mutation, indicating lack of rescue and
implying pathogenicity. Zebrafish co-injected with MO and ABCC6 mRNA carrying R64Q
mutation showed wild-type phenotype, similar to fish injected with MO together with
human wild-type (WT) ABCC6 mRNA.
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Figure 4. Cutaneous presentation, histopathology and mutation detection in a pediatric patient
with PXE

Author Manuscript

(a) Hyperpigmentation on the trunk (left) and yellowish papules in the axillary fossa (upper
right); Aberrant calcification in the dermis detected by von Kossa stain (bottom right); (b) A
heterozygous mutation, p.S479F, in the ENPP1 gene revealed by mutation analysis (arrow);
(c) Conservation of the serine-479 during evolution from zebrafish to human (outlined).
Scale bar = 100 mm.
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The missense variants of ABCC6 discovered in 22 Chinese patients with PXE, and bioinformatics predictions
of the consequence of the mutations

Author Manuscript

SIFT+

PolyPhen2+

p.Leu605Pro

Damaging (0)

Probably (1)

c.373G>A

p.Glu125Lys

Damaging (0.01)

Probably (0.997)

c.11C>A

p.Pro4His

Damaging (0)

Probably (0.957)

c.1256G>A

p.Arg419Gln

Damaging (0)

Probably (0.994)

c.2843T>C

p.Leu948Pro

Damaging (0)

Probably (0.988)

c.2126A>G

p. Glu709Gly

Damaging (0)

Probably (0.916)

c.2501T>C

p.Met834Thr

Tolerated (0.28)

Benign (0.047)

c.61C>T

p.pro21Ser

Tolerated (0.45)

Benign (0.209)

c.191G>A

p.Arg64Gin

Tolerated (0.21)

Benign (0.051)

c.26C>A

p.Ala9Glu

Damaging (0.02)

Benign (0.109)

c.268G>A

p.Ala90Thr

Tolerated (0.5)

Benign (0)

c.232G>A (x7)

p.Ala78Thr

Tolerated (0.18)

Benign (0.018)

c.4324G>A (x2)

p.Arg1442Thr

Tolerated (0.47)

Benign (0.188)

Mutations
At DNA level*

At protein level

c.1814T>C

*

The recurrent mutation in multiple alleles is indicated with the number of affected alleles in parentheses.

+

Indicates the prediction of the consequences of the mutations on the protein function with the score in parentheses.
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Zebrafish mRNA rescue assay
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Group*

ABCC6 mRNA variant

No. of embryos injected

Lethality (%)†

No injection

-

192

8.7

MO alone

-

68

79.3

MO+

p.R1141X

163

73.8

MO+

WT

80

23.4

MO+

p.P4H

71

85.9

MO+

p.A9E

94

83.0

MO+

p.P21S

93

79.0

MO+

p.R64Q

83

28.7

MO+

p.E125K

109

63.2

MO+

p.R419Q

48

89.1

MO+

p.E709G

64

65.6

MO+

p.M834T

118

64.4

MO+

p.L948P

109

71.1

*
Zebrafish embryos were injected at day 0 with an abcc6a morpholino (MO) alone or with human ABCC6 mRNA, either wild-type (WT) or
harboring different mutations.
†

The cumulative number of dead embryos at 4 days after injection, expressed as % of the total number of embryos injected.
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